# Association of estimated liver fibrosis with carotid but not femoral atherosclerotic burden: the ILERVAS cohort

**Authors:** Josep León-Mengíbar, María M. Malagón, Marcelino Bermúdez-López, José Manuel Valdivielso, Reinald Pamplona, Gerard Torres, Dídac Mauricio, Eva Castro, Elvira Fernández, Assumpta Caixàs, Marta Hernández, Carolina Lopez-Cano, Ana Gordon, Rocio Guzman-Ruiz, Kenneth Cusi, Albert Lecube

PMC · DOI: 10.3389/fendo.2025.1651689 · Frontiers in Endocrinology · 2026-01-06

## TL;DR

This study finds that higher liver fibrosis scores are linked to more severe carotid artery plaque buildup, but not in the femoral arteries, suggesting a specific connection between liver health and carotid atherosclerosis.

## Contribution

The study demonstrates that liver fibrosis indices are independently associated with carotid atherosclerosis in individuals without known liver disease.

## Key findings

- Higher FIB-4 scores correlate with increased carotid plaque prevalence, number, and area.
- FIB-4 and NFS are independent predictors of carotid atherosclerosis after adjusting for cardiovascular risk factors.
- No significant association was found between liver fibrosis indices and femoral atherosclerosis.

## Abstract

Advanced liver fibrosis, a key complication of metabolic dysfunction-associated steatotic liver disease, has been increasingly linked to extrahepatic conditions, including type 2 diabetes, obesity, and cardiovascular disease. However, the specific association of liver fibrosis in the development and progression of subclinical atheromatous disease across vascular territories remains poorly understood. This study evaluates the utility of two non-invasive indices to predict liver fibrosis and their associations with subclinical atheromatous plaque burden and distribution.

Atheromatous plaque burden (plaque presence, number, and total area) was assessed in the carotid and femoral territories via ultrasonography in 3,981 middle-aged participants without known cardiovascular disease, diabetes, or liver disease from the ILERVAS cohort (ClinicalTrials.gov Identifier: NCT03228459). The fibrosis-4 (FIB-4) and the NAFLD Fibrosis Score (NFS) were evaluated. FIB-4 risk categories were defined as low (<1.30), intermediate (1.30–2.67), and high (>2.67).

Participants in the intermediate and high-risk FIB-4 categories exhibited a higher prevalence of carotid atheromatous disease (56.8% vs. 49.5%, p<0.001), a greater number of plaques (p<0.001), and a larger total plaque area (p=0.007). Multivariable analyses confirmed FIB-4 as an independent predictor of carotid plaque burden (OR: 1.14, 95% CI 1.05-1.24, p=0.003), even adjusting for traditional cardiovascular risk factors. Moving from low to high FIB-4 cut-offs was associated with 12.6% higher odds of carotid atherosclerosis. NFS was also independently associated with carotid atheromatosis (OR 1.10, 95% CI 1.05–1.15, p<0.001). No significant associations were found in the femoral territory for either index.

Estimated liver fibrosis, particularly FIB-4, is a valuable marker for identifying carotid subclinical atherosclerosis in populations without known liver disease. These findings highlight the importance of vascular territory-specific evaluations and support their utility in integrated liver and cardiovascular risk assessment strategies.

## Linked entities

- **Diseases:** type 2 diabetes (MONDO:0005148), obesity (MONDO:0011122), cardiovascular disease (MONDO:0004995), metabolic dysfunction-associated steatotic liver disease (MONDO:0013209)

## Full-text entities

- **Diseases:** carotid atheromatosis (MESH:D016893), obesity (MESH:D009765), carotid atheromatous disease (MESH:D002340), fibrosis (MESH:D005355), type 2 diabetes (MESH:D003924), liver fibrosis (MESH:D008103), atherosclerosis (MESH:D050197), NAFLD Fibrosis (MESH:D065626), atheromatous disease (MESH:D058226), diabetes (MESH:D003920), liver disease (MESH:D008107), cardiovascular disease (MESH:D002318), metabolic dysfunction (MESH:D008659)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12816284/full.md

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12816284/full.md

## References

52 references — full list in the complete paper: https://tomesphere.com/paper/PMC12816284/full.md

---
Source: https://tomesphere.com/paper/PMC12816284